Clinical significance of sHER2‑ECD and calpain‑10 expression in tumor tissues of patients with breast cancer

Ding,Yawen; Ma,Ming; Li,Qingjing; Gao,Shejun; Li,Sainan; Liu,Junying; Geng,Cuizhi

doi:10.3892/or.2020.7564

Clinical significance of sHER2‑ECD and calpain‑10 expression in tumor tissues of patients with breast cancer

Authors:
- Yawen Ding
- Ming Ma
- Qingjing Li
- Shejun Gao
- Sainan Li
- Junying Liu
- Cuizhi Geng
View Affiliations

Affiliations: Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shiljiazhuang, Hebei 050011, P.R. China, Breast Center, The Fourth Hospital of Hebei Medical University, Shiljiazhuang, Hebei 050011, P.R. China, Department of Pathology, The Fourth Hospital of Hebei Medical University, Shiljiazhuang, Hebei 050011, P.R. China
Published online on: March 26, 2020 https://doi.org/10.3892/or.2020.7564
Pages: 2093-2104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human epidermal growth factor receptor 2 (HER2) is composed of an extracellular domain (ECD), a lipophilic transmembrane region and an intracellular domain (ICD). The most commonly used method to determine the status of HER2 is immunohistochemistry. However, false‑negative results are sometimes given, which causes some patients to lose the opportunity for anti‑HER2 therapy. We found that calpain‑10 may prohibit HER2‑ECD into peripheral blood resulting in a HER2‑negative result by the immunohistochemical method. We enrolled 289 patients into our experiment to assess the relationship between sHER2‑ECD and calpain‑10. The results showed that there was a positive correlation between sHER2‑ECD and calpain‑10. Moreover, we also investigated the prognostic values of sHER2‑ECD and calpain‑10 in breast cancer patients. According to the follow‑up results, positive sHER2‑ECD and tissue calpain‑10 were indicative of a poor prognosis in breast cancer patients. Subsequently, we further validated the relationship between the two molecules in in vitro experiments. In the in vitro experiments, the level of HER2‑ECD in the culture medium was increased or decreased with a decrease or increase in calpain‑10 by transfection technology, showing an inverse association. The results indicated that sHER2‑ECD and tissue calpain‑10 levels were powerful factors to assess the status of HER2. In combination with tissue HER2 detection, the occurrence of false‑negative HER2 was reduced, providing patients with additional treatment opportunities. In conclusion, sHER2‑ECD and tissue calpain‑10 may be used as new prognostic indices for breast cancer.

View Figures

View References

1	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar
2	Harari D and Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 19:6102–6114. 2000. View Article : Google Scholar
3	Panis C, Pizzatti L, Corrêa S, Binato R, Lemos GF, da Silva do Amaral Herrera AC, Seixas TF, Cecchini R and Abdelhay E: The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 357:186–195. 2015. View Article : Google Scholar
4	Carney WP, Neumann R, Lipton A, Leitzel K, Ali S and Price CP: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 49:1579–1598. 2003. View Article : Google Scholar
5	Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, et al: Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther. 5:657–664. 2006. View Article : Google Scholar
6	Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M and Bendahl PO: HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat. 109:351–357. 2008. View Article : Google Scholar
7	Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al: Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
9	Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, et al: Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol. 20:3628–3636. 2002. View Article : Google Scholar
10	Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A and Heys SD: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast. 12:320–327. 2003. View Article : Google Scholar
11	Qi M, Li JF, Xie YT, Lu AP, Lin BY and Ouyang T: Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer. Breast Cancer Res Treat. 123:197–202. 2010. View Article : Google Scholar
12	Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, et al: Evaluation of serum HER2 extracellular domain in early breast cancer patients: Correlation with clinicopathological parameters and survival. Ann Oncol. 19:883–890. 2008. View Article : Google Scholar
13	Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL and Pichon MF: Serum HER-2 extracellular domain: Relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers. 19:14–22. 2004. View Article : Google Scholar
14	Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, et al: Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 86:9–18. 2004. View Article : Google Scholar
15	Fehm T, Jäger W, Krämer S, Sohn C, Solomayer E, Wallwiener D and Gebauer G: Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res. 24:1987–1992. 2004.
16	Wang T, Zhou J, Zhang S, Bian L, Hu H, Xu C, Hao X, Liu B, Ye Q, Liu Y and Jiang Z: Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients. Clin Chim Acta. 458:23–29. 2016. View Article : Google Scholar
17	Pohlmann PR, Mayer IA and Mernaugh R: Resistance to trastuzumab in breast cancer. Clin Cancer Res. 15:7479–7491. 2009. View Article : Google Scholar :
18	Moretti D, Del Bello B, Allavena G and Maellaro E: Calpains and cancer: Friends or enemies? Arch Biochem Biophys. 564:26–36. 2014. View Article : Google Scholar
19	Storr SJ, Lee KW, Woolston CM, Safuan S, Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO and Martin SG: Calpain system protein expression in basal-like and triple-negative invasive breast cancer. Ann Oncol. 23:2289–2296. 2012. View Article : Google Scholar :
20	Chan D, Tsoi MY, Liu CD, Chan SH, Law SY, Chan KW, Chan YP, Gopalan V, Lam AK and Tang JC: Oncogene GAEC1 regulates CAPN10 expression which predicts survival in esophageal squamous cell carcinoma. World J Gastroenterol. 19:2772–2780. 2013. View Article : Google Scholar :
21	Leloup L and Wells A: Calpains as potential anti-cancer targets. Expert Opin Ther Targets. 15:309–323. 2011. View Article : Google Scholar :
22	Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, Mc Kenzie S, Hayes D, Kufe D, DeLellis R, et al: Detection and quantitation of the human neu protein. J Tumor Marker Oncol. 6:53–72. 1991.